Background: Outcomes of treating gestational diabetes mellitus (GDM) are not well-established.
G
estational diabetes mellitus (GDM) is defined as glucose intolerance first discovered in pregnancy. It predicts risk for overt diabetes in women. The more immediate risk for adverse outcomes of GDM in the mother and child is less well-established.
The prevalence of GDM ranges from 1.1% to 25 .5% of pregnancies in the United States (1) (2) (3) and is influenced by diagnostic criteria and population characteristics, such as ethnicity. The incidence of this condition has increased over the past decades in parallel with the increase in rates of obesity and type 2 diabetes mellitus, and this trend is expected to continue.
Initial treatment of GDM involves diet modification, glucose monitoring, and moderate exercise. When dietary management does not achieve desired glucose control, insulin or oral antidiabetic medications may be used (4) . Increased prenatal surveillance and changes in delivery management may also occur.
A report commissioned by the U.S. Preventive Services Task Force in 2008 found that treatment of women with mild GDM diagnosed after 24 weeks' gestation improved maternal and neonatal health outcomes (5) . Specifically, on the basis of 1 study, they found a reduction in "any serious perinatal complication," which included death, shoulder dystocia, bone fracture, and nerve palsy (6) . The number of events for many of the individual outcomes was extremely small, which did not provide adequate evidence to make conclusions for individual outcomes. The same study also found less depression and a trend to better quality of life 3 months after parturition and reduced maternal hypertension in the treated group (6) .
Potential harms of GDM treatment may include small-for-gestational-age neonates; maternal stress; and additional costs, including those associated with laboratory testing as well as patient and clinician time (7) . Anxiety of health care providers over the diagnosis could result in unnecessary or overly aggressive fetal and neonatal surveillance and delivery management. The purpose of this review is to evaluate whether treatment of GDM modifies outcomes of mothers and their offspring and whether it is associated with any harms.
METHODS
An a priori protocol was followed. Questions were developed by the Office of Medical Applications of Research and the U.S. Preventive Services Task Force. A technical expert panel that included representatives from both organizations provided content and methodological expertise. The full technical report is available at http://effective healthcare.ahrq.gov/index.cfm/search-for-guides-reviews -and-reports/?productidϭ1295&pageactionϭdisplayproduct.
Data Sources and Searches
We searched for trials and cohort studies published in English from 1995 to May 2012 in MEDLINE (Ovid interface) (Appendix Table 1 We also searched trial registries and the Web sites of relevant professional associations and research groups for conference abstracts and proceedings between 2010 and 2012. We evaluated the reference lists of relevant reviews and included studies.
Study Selection
Two reviewers independently screened titles, keywords, and abstracts. We retrieved the full text for any study that was considered potentially relevant by at least 1 reviewer. Two reviewers independently assessed each fulltext article by using a detailed form. We resolved disagreements through discussion. We included studies if they were randomized, controlled trials (RCTs) or non-RCTs or cohort studies; involved pregnant women with no known preexisting diabetes; compared any treatment of GDM with no treatment; and reported short-and long-term maternal, fetal, neonatal, and child outcomes that the technical panel deemed important.
Data Extraction and Quality Assessment
One reviewer extracted data by using a structured, electronic form, and a second reviewer checked the data for accuracy and completeness. Discrepancies were resolved through consensus. We extracted information on study characteristics, populations, interventions, outcomes, and results.
Two reviewers independently assessed the methodological quality of included studies and resolved disagreements through discussion. We used the Cochrane risk-ofbias tool to assess RCTs (8) and the Newcastle-Ottawa Scale to assess cohort studies (9) .
Data Synthesis and Analysis
Two independent reviewers graded the strength of evidence by using the Evidence-based Practice Center Grading of Recommendations Assessment, Development and Evaluation approach (10) . We resolved discrepancies by discussion. We assessed 4 major domains (risk of bias, consistency, directness, and precision) and summarized the overall strength of evidence for each outcome as high, moderate, or low. When no studies were available for an outcome or the evidence did not permit estimation of an effect, we rated strength of evidence as insufficient.
We described the results of studies qualitatively and in evidence tables. We performed meta-analyses when studies were sufficiently similar in terms of statistical homogeneity (that is, I
2 Յ 75%). We used the Mantel-Haenszel method for relative risks and the inverse variance method for pooling mean differences.
We combined results by using the random-effects model (11) . For dichotomous outcomes, we computed relative risk to estimate between-group differences. If no event was reported in 1 treatment group, a correction factor of 0.5 was added to each cell of the 2 ϫ 2 table to obtain estimates of the relative risk.
For continuous variables, we calculated mean differences for individual studies. We reported all results with 95% CIs and used Review Manager Version 5.0 (The Cochrane Collaboration, Copenhagen, Denmark) to perform meta-analyses.
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GDM. The 2 largest RCTs used different glucose thresholds for entry in their trials: World Health Organization (6) and Carpenter-Coustan criteria with a fasting glucose level less than 5.3 mmol/L (95 mg/dL) (12); however, the mean glucose levels of women at study entry were similar between these 2 studies. Risk of bias was low for 1 trial (6), unclear for 3 trials (12) (13) (14) , and high for 1 trial (15) . All cohort studies were considered high quality, with overall scores of 7 to 9 on a 9-point scale.
Benefits of Treating GDM
The Table and Appendix Table 2 (available at www .annals.org) show results for maternal outcomes. Moderate evidence from 3 RCTs showed less preeclampsia with treatment (Appendix Figure 2 , available at www.annals .org). In 2 of these trials, there was no difference between groups in gestational age at delivery. The strength of evidence for maternal weight gain was insufficient because of inconsistency across studies and imprecise effect estimates (Appendix Figure 3 , available at www.annals.org). Two RCTs showed no difference (13, 15) , whereas 2 large RCTs showed less weight gain with treatment (6, 12) . Given the high body mass index (BMI) of the women studied, less gestational weight gain in the treatment group would be beneficial. One RCT reported on BMI at delivery and showed lower BMI with treatment; however, this evidence was considered insufficient. There was no evidence from the included studies for long-term maternal outcomes, such as type 2 diabetes mellitus, obesity, and hypertension.
The Table and Appendix Table 3 (available at www .annals.org) show the findings for fetal, neonatal, or child outcomes. Evidence was insufficient for birth injury due to imprecision (low number of events and participants across studies) and inconsistency (2 RCTs showed no difference [12, 15] , and 1 cohort study showed fewer cases with treatment [18] ). Moderate evidence showed fewer cases of shoulder dystocia with treatment (Figure 1) . For other injury outcomes (that is, brachial plexus injury and clavicular fractures), results were inconsistent across study designs, with the RCTs showing no differences and the cohort study showing fewer cases with treatment.
For outcomes related to birthweight (including birthweight Ͼ4000 g, actual birthweight, and large-forgestational-age neonates), lower weights or fewer cases were observed with treatment. The strength of evidence was moderate for birthweight Ͼ4000 g (Figure 1 ). There was no difference in hyperbilirubinemia for RCTs (low strength of evidence), whereas the cohort study showed significantly less hyperbilirubinemia in the treated group.
There were no differences in perinatal death, although the number of events was extremely low (Ͻ0.5%). Randomized, controlled trials showed no difference between groups for the respiratory distress syndrome, whereas 1 cohort study found fewer "respiratory complications" (17) in This online-first article will have minor typographical differences from the final, printed version.
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the treated group; overall respiratory distress syndrome was rare (4.3% across all studies). Several studies assessed Apgar scores; although differences were found for the Apgar score at 1 minute, no differences were observed at 5 minutes. One RCT followed a subset of the offspring for 7 to 11 years and found no differences for impaired glucose tolerance or type 2 diabetes mellitus (insufficient strength of evidence). No differences were observed in single studies that assessed offspring with BMIs greater than the 95th percentile (7-to 11-year follow-up) and greater than the 85th percentile (4-to 5-year follow-up). Overall, pooled results showed no difference in BMI (low strength of evidence).
Harms of Treating GDM
One RCT assessed maternal depression and anxiety at 6 weeks after study entry and 3 months after parturition (6) . There was no difference between groups in anxiety at either time point. Depression rates were lower in the treatment group 3 months after parturition (Appendix Table 2 ).
Moderate evidence from 4 RCTs showed no difference in small-for-gestational-age neonates. Pooled results from 4 RCTs showed no difference between groups in neonatal hypoglycemia and no statistical heterogeneity (Figure 1) .
Two cohort studies showed inconsistent results, which may be partly due to different definitions of hypoglycemia used across the studies and different protocols for screening neonates for hypoglycemia. Overall, the strength of evidence was low, suggesting that further study may change the results of our findings (Table) .
Low evidence showed no difference overall in admission to the neonatal intensive care unit (Appendix Figure  4 , available at www.annals.org). One trial was an outlier, with significantly more neonatal intensive care unit admissions in the treated group. Two RCTs reported on the number of prenatal visits and found more visits among the treatment groups. The strength of evidence for induction of labor was insufficient because of lack of precision and inconsistency across studies, with no difference found for the RCTs overall. There was low evidence of no differences between groups for cesarean delivery (Figure 2) or unplanned cesarean delivery.
DISCUSSION
Moderate evidence showed that treatment of GDM reduced preeclampsia, shoulder dystocia, and macrosomia (birthweight Ͼ4000 g). These outcomes, specified a priori This online-first article will have minor typographical differences from the final, printed version.
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Benefits In terms of harms, there was no evidence for some of the outcomes stipulated in the protocol, including costs and resource allocation, although there were more prenatal visits in the treatment groups. No difference was found in small-for-gestational-age neonates, which may be due to inadequate power to detect differences because of the small number of events. No differences were found for admission to the neonatal intensive care unit or rate of induction of labor. However, there was heterogeneity in these outcomes that may be attributable to different site-specific policies and procedures, study protocols, and practice patterns. Low evidence showed no difference in rates of cesarean delivery.
Our results are consistent with other recent systematic reviews showing some evidence of benefit of treating GDM for select maternal and infant outcomes yet little evidence of an effect on patient-important outcomes (for example, perinatal or neonatal mortality). This is probably due to the infrequent occurrence of these events and a resulting lack of power across the studies to adequately assess for differences (24, 25) .
Several caveats related to this body of evidence should be considered when interpreting and applying the results of this review. First, although we found differences in preeclampsia, macrosomia, and shoulder dystocia, most such events occur in pregnant women without GDM (26) . Such factors as maternal weight and gestational weight gain have been shown to impart greater risk for these outcomes, particularly in women diagnosed with GDM at lower glucose thresholds (27, 28) . For example, analyses adjusting for these variables show that glycemia accounted for only 1.7% of the risk for large-for-gestational-age neonates (27) . Second, where reported, definitions of preeclampsia varied (for example, a blood pressure of 140/90 mm Hg on 2 occasions 4 hours apart, these criteria with laboratory measures indicative of preeclampsia, or an increase in blood pressure medications). Preeclampsia events in our pooled analysis may have included women with the much-lessserious condition of gestational hypertension; however, a study that used the more rigorous definition showed a treatment benefit (12) . Preeclampsia occurs in 3% to 5% of pregnancies (29), and the risk for this condition attributable to GDM is probably small (30). Third, this review assessed the risks and benefits of treating GDM but not those of screening for this condition. Of note, our larger technical report, which addressed screening, found no randomized trials examining the effect of screening on health outcomes (http://effectivehealthcare.ahrq.gov/index.cfm /search-for-guides-reviews-and-reports/?productidϭ1295& pageactionϭdisplayproduct).
Evidence was very limited for 2 outcomes of particular interest to stakeholders. The first was patient anxiety associated with a diagnosis of GDM. A single study assessed depression and anxiety in a subgroup of a larger RCT. It found no difference between groups in anxiety at 6 weeks after study entry and 3 months after parturition, although the treatment group had lower rates of depression at 3 months after parturition. Research has shown that women with GDM had a higher level of anxiety at the time of the first GDM assessment than glucose-tolerant women; however, these differences in anxiety scores did not persist before delivery (31). Further, a survey of women 3 to 5 years after diagnosis of GDM showed more concern about their own health and rated their children's health poorer than matched control participants (32). The second outcome was metabolic changes in the children born to mothers with GDM. Follow-up of offspring from participants in 2 RCTs (6, 16) did not show any treatment effect of GDM on metabolic outcomes of the children.
Further study of the long-term metabolic effect on offspring whose mothers have been treated for GDM is warranted. Well-conducted prospective cohort studies of the real-world effect of GDM treatment on health care utilization are needed. Research is also needed to help determine the glucose thresholds and treatment targets at which GDM treatment benefits outweigh the risks of treatment and no treatment.
The IDEAL (Investigation of Dietary Advice and Lifestyle for Women With Borderline Gestational Diabetes) study, an RCT to assess the effect of treating women with very mild glucose impairment in pregnancy, is under way. Randomized, controlled trials investigating the care of women diagnosed with GDM, including fetal surveillance protocols, are needed to guide obstetric investigations and management of GDM. Such work may help avoid unnecessary interventions that are driven by the apprehension of health care providers.
The review process had several limitations. We limited the search dates from 1995 onward on the basis of advice from our technical expert panel. Our results are consistent with other systematic reviews on this topic that included studies before 1995 (24, 25) . We included only studies published in English. Most studies were conducted in North America or Australia. Most of the North American studies included mixed racial populations and are probably applicable to the general U.S. population. We included cohort studies because an earlier review (5) found few RCTs; results from cohort studies should be interpreted cautiously, particularly when they differ from those of the RCTs.
In summary, evidence supports benefits of treating mild GDM. Specifically, treatment of GDM results in lower incidence of preeclampsia, macrosomia, large-forgestational-age infants, and shoulder dystocia; however, the risk for these outcomes attributable to GDM is low, particularly when glucose levels are modestly elevated. Current
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